OXB — Oxford BioMedica Cashflow Statement
0.000.00%
Last trade - 00:00- £684.30m
- £735.54m
- £168.74m
Annual cashflow statement for Oxford BioMedica, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 19.9 | -46 | -189 | -47.3 | -31.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 5.03 | 1.53 | 106 | 8.55 | 4.24 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -11.9 | 5.47 | 25 | -34.4 | 8.36 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 25.5 | -12.6 | -28.5 | -50.7 | 0.507 |
| Capital Expenditures | -9.46 | -16.3 | -9.83 | -7.5 | -4.76 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -40.2 | 12.6 | 13.1 | -0.962 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -9.46 | -56.5 | 2.81 | 5.63 | -5.72 |
| Financing Cash Flow Items | -0.873 | -13.9 | -10.2 | -9.43 | -14.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 46.2 | 98.6 | -12.7 | 2.91 | 42.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 62.2 | 32.3 | -37.6 | -43.1 | 36.2 |